Loading…
Employees: 420
Size Beijing Leadman Biochemistry (300289.SZ) is a China Health Care company (Medical Specialties) with a market value of $483M, the 3933rd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥5.95 on 6 Nov 2026.
Performance Over six months the shares fell 11.3%, against -13.4% for the median peer and -16.4% for the China market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue fell 5.9% over the last twelve months (peer median +1.7%); the operating margin is -11.6% (peer median 6.3%).
Valuation It trades at 7.5× enterprise value to sales against a peer median of 4.2× (3rd most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 36% a year for seven years (Req g). Recent delivered growth is -7%, so the hurdle is +42 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 11.1 points below its cost of capital (7.7% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥312M | CN¥324M | CN¥360M | CN¥450M | CN¥693M |
| Revenue growth | — | -10% | -20% | -35% | — |
| Gross profit | CN¥100M | CN¥116M | CN¥131M | CN¥199M | CN¥235M |
| EBITDA | CN¥13.7M | CN¥23.8M | CN¥22.0M | CN¥82.0M | CN¥77.7M |
| Net income | -CN¥25.9M | -CN¥23.0M | -CN¥75.1M | CN¥15.3M | -CN¥56.3M |
| Free cash flow | CN¥24.2M | CN¥17.7M | CN¥40.8M | CN¥116M | CN¥74.1M |
| Capital expenditure | CN¥20.7M | CN¥17.6M | CN¥29.2M | CN¥18.7M | CN¥39.1M |
| Total debt | CN¥11.9M | CN¥13.4M | CN¥14.1M | CN¥18.2M | CN¥23.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300289.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.3% | -4.6% | 8th highest of 21 |
| 6-month return | -11.3% | -13.4% | 10th highest of 21 |
| Distance from 52-week high | -42.8% | -32.8% | 7th lowest of 21 |
| Revenue growth (TTM) | -5.9% | +1.7% | 5th lowest of 21 |
| Operating margin | -11.6% | 6.3% | 5th lowest of 21 |
| EV / Sales | 7.5× | 4.2× | 3rd most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 35.5% | 10.8% | 2nd most demanding of 13 |
| Growth delivered (Del g) | -6.9% | +8.8% | 2nd lowest of 13 |
| Hurdle (Req g minus delivered) | +42.5 pp | +6.5 pp | most demanding of 13 |
| ROIC minus cost of capital | -11.1 pp | -2.5 pp | 5th lowest of 18 |
| Net debt / EBITDA | -66.1× | -0.8× | least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Leadman Biochemistry 300289.SZ | China | $483M | -11% | -6% | -12% | 7.5× | 35.5% | -6.9% |
| MiMedx MDXG | United States | $483M | -8% | -23% | -8% | 1.2× | 11.5% | +11.0% |
| CellaVision CEVI.ST | Sweden | $485M | +68% | +2% | 23% | 6.0× | 6.5% | +10.0% |
| WELL LEAD MEDICAL 603309.SS | China | $486M | -19% | +1% | 15% | 2.0× | -5.6% | +7.7% |
| China Isotope & Radiation 1763.HK | Hong Kong | $478M | -38% | -5% | 13% | n/a | n/a | n/a |
| Shofu 7979.T | Japan | $475M | +27% | +7% | 14% | 1.6× | n/a | n/a |
| Shanghai Kindly Enterprises Development 603987.SS | China | $474M | -14% | 0% | 11% | 1.6× | 3.8% | -2.8% |
| Guangdong Shirongzhaoye 002016.SZ | China | $473M | -28% | -31% | 3% | 4.0× | 22.2% | -11.7% |
| AngioDynamics ANGO | United States | $493M | +5% | +8% | -6% | 1.4× | n/a | n/a |
| Huaren Pharmaceutical 300110.SZ | China | $472M | -16% | -3% | 6% | 3.5× | 6.7% | +0.3% |
| Revenio REG1V.HE | Finland | $494M | -22% | +16% | 14% | 5.5× | 19.3% | +12.4% |
| Guangzhou Jet Bio-Filtration 688026.SS | China | $471M | +40% | +5% | 11% | 5.2× | 22.1% | +2.2% |
| Jiangsu Huayang Intelligent Equipment 301502.SZ | China | $470M | +35% | -5% | 2% | 7.1× | 42.6% | +0.4% |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $499M | -14% | -9% | -51% | n/a | n/a | n/a |
| Jenscare Scientific 9877.HK | Hong Kong | $463M | -32% | +993% | -106% | 20.2× | n/a | n/a |
| Eiken Chemical 4549.T | Japan | $454M | -29% | +4% | 6% | 1.5× | n/a | n/a |
| AVITA Medical RCEL | United States | $513M | +304% | +1% | -47% | 7.3× | n/a | n/a |
| Hunan Sundy Science and Technology 300515.SZ | China | $453M | -13% | +10% | 27% | 3.7× | 0.9% | +15.6% |
| PROTEINA 468530.KS | South Korea | $450M | -2% | -59% | -1,178% | 410.3× | n/a | n/a |
| Brainsway Ltd Sponsored ADR BWAY | United States | $450M | -35% | +32% | 12% | 6.5× | 34.3% | +18.8% |
| Delcath Systems DCTH | United States | $518M | +30% | +36% | -2% | 4.5× | 10.1% | +120.2% |